Summary Omeros recently spiked on release of new Phase II drug data for OMS-721. The stock quickly gave up almost all of these gains once the details of this trial were better understood. Omeros had previously been hitting a new 52-week low of $11.93 due to the failed launch of its only commercial product, Omidria….

Read More